Cargando…
IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
Immunotherapy has become the major treatment for tumors in clinical practice, but some intractable problems such as the low response rate and high rates of immune-related adverse events still hinder the progress of tumor immunotherapy. Hence, it is essential to explore additional immunotherapy treat...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277907/ https://www.ncbi.nlm.nih.gov/pubmed/35831836 http://dx.doi.org/10.1186/s40364-022-00394-0 |